Anthera Pharma (ANTH) Announces Withdrawal of Nasdaq Hearing Request, Suspension of Trading on NASDAQ Jun 27, 2018 08:24AM
Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets Jun 27, 2018 08:00AM
Anthera Pharma (ANTH) Phase 3 Clinical Study of Sollpura Did Not Meet Primary Endpoint Mar 12, 2018 08:01AM
Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura Mar 12, 2018 08:00AM
Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference Mar 7, 2018 08:30AM


Mar 6, 2018 02:46PM Anthera Pharma (ANTH) Says it's Compliant with Nasdaq Listing Criteria
Mar 6, 2018 02:45PM Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria
Mar 5, 2018 04:05PM Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results
Feb 8, 2018 08:30AM Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orphan Drug Day
Feb 5, 2018 08:30AM Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura
Jan 25, 2018 04:41PM Anthera Pharma (ANTH) Receives Positive Nasdaq Listing Determination
Jan 25, 2018 04:30PM Anthera Receives Positive Nasdaq Listing Determination
Jan 22, 2018 08:33AM Anthera Pharma (ANTH) Reports Positive Outcome of Second Interim Futility Analysis in Phase 3 RESULT Clinical Study of Sollpura
Jan 22, 2018 08:30AM Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter
Jan 9, 2018 05:15PM Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
Jan 8, 2018 08:30AM Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders
Jan 3, 2018 08:30AM Anthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, Manufacturing
Dec 11, 2017 08:33AM Anthera Pharma (ANTH) Announces Positive Outcome of Interim Futility Analysis in Phase 3 RESULT Clinical Study of Sollpura
Dec 11, 2017 08:30AM Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
Dec 11, 2017 08:30AM Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
Nov 17, 2017 04:06PM Anthera Pharma (ANTH) Receives Nasdaq Listing Determination Notice, Plans Appeal
Nov 17, 2017 04:05PM Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal
Nov 9, 2017 08:38AM Anthera Pharma (ANTH) Completes Recruitment in Phase 3 RESULT Clinical Study of Sollpura
Nov 9, 2017 08:30AM Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
Nov 6, 2017 08:30AM Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results
Nov 5, 2017 08:30AM Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting
Nov 2, 2017 08:30AM Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference
Nov 1, 2017 05:00PM Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting
Sep 7, 2017 08:30AM Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis
Sep 6, 2017 08:30AM Anthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference
Sep 5, 2017 08:30AM Anthera Pharmaceuticals to Participate in the Citi 12th Annual Biotech Conference
Aug 28, 2017 08:37AM Anthera Pharma (ANTH) Reports Top Line Final Data from Extension Period of Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgAN
Aug 28, 2017 08:30AM Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
Aug 14, 2017 08:37AM Anthera Pharma (ANTH) Says RESULT Phase 3 Clinical Study of Sollpura Approved by ECFS CTN
Aug 14, 2017 08:30AM Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network
Aug 9, 2017 04:01PM Anthera Pharma (ANTH) Confirms FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
Aug 9, 2017 04:00PM Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
Aug 9, 2017 08:30AM Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results
May 10, 2017 04:02PM Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results
Feb 27, 2017 04:05PM Anthera Pharmaceuticals Provides Business Update and Reports 2016 Fourth Quarter and Fiscal Year Financial Results
Nov 4, 2016 08:30AM Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results
Aug 9, 2016 08:35AM Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
May 9, 2016 08:38AM Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results
Apr 27, 2016 04:09PM Anthera Pharma (ANTH) Names New Board Member
Apr 27, 2016 04:05PM Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
Mar 10, 2016 08:38AM Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results
Mar 7, 2016 08:37AM Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical Officer